Motility disorders in children with intestinal failure: a national tertiary referral center experience

Audelia Eshel Fuhrer1,2, Stephanie Sukhotnik3, Hadar Moran-Lev4,5,6

  • 1Department of Pediatric Surgery, Dana-Dwek Children's Hospital, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel. odly86@gmail.com.

Insights

Intestinal dysmotility (ID) is a frequent complication in pediatric intestinal failure (IF) and short bowel syndrome (SBS). Tapering enteroplasty (STEP) effectively treated ID in these patients, improving outcomes.

Area of Science:

  • Pediatric Gastroenterology
  • Intestinal Failure Research
  • Surgical Innovation

Background:

  • Intestinal dysmotility (ID) frequently complicates pediatric intestinal failure (IF) and short bowel syndrome (SBS).
  • ID contributes to significant morbidity and hinders enteral nutrition (EN) advancement in affected children.
  • Understanding ID's clinical features and complications is crucial for managing IF and SBS.

Purpose of the Study:

  • To investigate the clinical characteristics and complications of intestinal dysmotility (ID) in children with IF and short bowel syndrome (SBS).
  • To identify risk factors and clinical manifestations associated with ID in pediatric IF and SBS patients.
  • To evaluate the effectiveness of surgical interventions for ID in this population.

Main Methods:

  • Retrospective chart review of 42 children with IF/SBS treated between 2003-2022.
  • Patients categorized into SBS and non-SBS groups, with SBS further divided into those with and without ID.
  • ID identification based on clinical, radiological, and functional assessments; analysis of demographics, anatomy, complications, and outcomes.

Main Results:

  • ID was the primary cause of IF in 80% of non-SBS patients and occurred in 56% of SBS patients.
  • SBS patients with ID exhibited specific characteristics, including shorter residual small bowel length and absence of the ileocecal valve (ICV).
  • Common ID symptoms included food intolerance, distension, vomiting, malabsorption, and constipation; complications included failure to thrive (FTT) and bacterial overgrowth.

Conclusions:

  • Intestinal dysmotility is the leading complication in SBS and a major cause of IF in non-SBS pediatric patients.
  • ID presents with diverse clinical manifestations and high morbidity, significantly impacting patient outcomes.
  • Tapering enteroplasty (STEP) demonstrated significant success in treating ID, leading to improved intestinal function and TPN weaning.
Abstract

Related Concept Videos

Gastrointestinal Motility Disorders01:20

Gastrointestinal Motility Disorders

Gastrointestinal or GI motility disorders are characterized by irregular gastrointestinal tract movements, disrupting food transit from the mouth to the anus. They are caused by damage or dysfunction in gut muscles or nerves. These disorders can cause symptoms such as severe constipation, diarrhea, abdominal pain, and swallowing difficulties. Disorders can affect any segment of the GI tract and range widely in severity, from common conditions like GERD to life-threatening conditions like...
562
Imaging Studies III: Gastrointestinal Motility Studies and Virtual Colonoscopy01:26

Imaging Studies III: Gastrointestinal Motility Studies and Virtual Colonoscopy

This lesson explores three gastrointestinal imaging techniques: radionuclide testing, colonic transit studies, and virtual colonoscopy.
Radionuclide Testing
Radionuclide testing is a sophisticated medical technique for assessing gastrointestinal motility. It focuses on gastric emptying and colonic transit time. Radioactive markers track the movement of food through the digestive system, providing insights into gastrointestinal disorders.
In gastric emptying studies, a meal's liquid and...
136
Drugs Affecting GI Tract Motility: Antimicrobials as Antidiarrheal Agents01:18

Drugs Affecting GI Tract Motility: Antimicrobials as Antidiarrheal Agents

Acute diarrhea, a common gastrointestinal disturbance, is characterized by the rapid evacuation of fluid stools, leading to an excessive weight in fluid. This condition typically arises from disorders affecting intestinal water and electrolyte transport. It can be triggered by an increased osmotic load within the intestine, excessive secretion of electrolytes and water, mucosal exudation of protein and fluid, or altered intestinal motility. The primary risks of acute diarrhea are dehydration...
193
Chronic Bowel Disorders: Introduction01:17

Chronic Bowel Disorders: Introduction

Chronic bowel diseases are a group of long-term conditions affecting the digestive tract, characterized by inflammation and damage to the gut lining. These conditions primarily include irritable bowel syndrome and inflammatory bowel disease.
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...
526
Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists01:23

Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists

Serotonin, a crucial neurotransmitter synthesized by enterochromaffin cells, plays a cardinal role in regulating gastrointestinal (GI) motility. With over 90% of the body's total serotonin in the GI tract, its influence on digestive processes is profound. Serotonin is swiftly released upon various stimuli, such as food boluses or certain drugs, triggering intrinsic sensory neurons in the myenteric plexus and extrinsic vagal and spinal sensory neurons. This leads to the activation of the...
377
Drugs Affecting GI Tract Motility: Dopamine Receptor Antagonists01:28

Drugs Affecting GI Tract Motility: Dopamine Receptor Antagonists

Prokinetic agents are specialized medications that stimulate gastrointestinal (GI) motility, promoting food movement through the GI tract. Dopamine, an inhibitory neurotransmitter, plays a significant role in this process, reducing GI motility and indirectly controlling the speed of digestion. Dopamine receptor antagonists, such as metoclopramide and domperidone, offer a unique advantage as prokinetic agents. By blocking the dopamine receptors, these drugs increase GI motility, improving food...
551